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ABSTRACT
This commentary analyzes the Liraglutide Effect
and Action in Diabetes: Evaluation of
Cardiovascular Outcome Results (LEADER) trial,
which has reported the cardiovascular benefits of
liraglutide. It places the results of this seminal trial
in the context of the evolution of diabetes care,
compares them with other recently published
cardiovascular outcome trials, and suggests novel
mechanisms to explain the benefits and
properties of liraglutide. The editorial discusses
thepotential impact thatLEADERwillhaveonthe
prevention and management of diabetes and its
vascular complications.
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Modern diabetology, which traces its
beginning to the discovery of insulin, has
witnessed various landmark events, and
experienced significant changes in its
approach since then. Screening tests,
diagnostic cutoffs, investigative modalities,
parameters for follow-up, treatment strategies
and management goals, all have evolved over
the past century.
In general, we have moved from an
autocratic, empirical, physician-oriented,
gluco-centric biomedical model to a
pantisocratic, evidence-based, patient-centered,
comprehensive metabolic control approach
based upon a biopsychosocial framework [1–3].
Instead of focusing solely on glycemic
indicators, we now rely on comprehensive
parameters, including weight, blood pressure
and lipids, to assess quality of care. We have
also begun measuring meaningful outcomes,
such as disease-free life span, survival rates, and
time to important events such as stroke,
myocardial infarction and heart failure,
instead of relying on surrogate markers.
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These developments have been made
possible by multiple advances in science.
Greater knowledge of etiology, pathogenesis,
and natural history of diabetes, coupled with a
multi-dimensional, holistic understanding of
diabetic complications has led to changes in
our approach to diabetes. These changes have
been facilitated by technological improvements
in diagnostic and treatment interventions,
which have allowed the achievement of
hitherto difficult to achieve targets and goals.
CARDIOVASCULAR OUTCOME
TRIALS
Modern diabetes care expects not only
symptomatic and biochemical control from
glucose-lowering drugs, but also requires
long-term improvement in micro-vascular
health, macrovascular health, and overall
survival. While the impact of such drugs on
glucose control can be assessed by short-term
trials, their effect on cardiovascular outcomes
(CVO) needs studies of longer duration. Such
trials, termed CVO trials, are mandatory for all
newly registered drugs, as cardiovascular (CV)
disease is the main contributor to mortality in
persons with diabetes [4]. Newer molecules such
as saxagliptin, sitagliptin, empagliflozin and
lixisenatide have reported CVO in the past few
years, adding to our knowledge and
understanding [5–8].
The LEADER Trial
The Liraglutide Effect and Action in Diabetes:
Evaluation of Cardiovascular Outcome Results
(LEADER) trial (NCT01179048) is one such
landmark trial [9]. The results of LEADER have
been discussed on various platforms. In this
commentary, we summarize the findings of
LEADER (Table 1), suggest novel hypotheses to
explain the benefits of liraglutide, and discuss
how this trial will influence the future of
diabetes care.
Results
In LEADER, the primary outcome was a
composite of three major adverse
cardiovascular (CV) events (three-point
MACE), defined as first occurrence of death
from CV causes, non-fatal myocardial infarction
(MI), or non-fatal stroke. Table 1 summarizes
the findings of this study, which revealed a
significant 13% reduction in the primary
outcome, a significant 22% fall in CV death,
and a numerical, but statistically
non-significant lowering of risk of non-fatal
MI and non-fatal stroke [9].
Death from CV causes was reduced in
participants taking liraglutide in LEADER
(hazard ratio (HR) 0.8). A similar lowering of
all-cause mortality was noticed in this group
(HR 0.8 5). As 219 out of 381 deaths in the
liraglutide arm (57.5%) and 278 out of 447
deaths in the placebo arm (62.2%) occurred due
to CV causes, the major driver of improvement
in all-cause death seemed to be the CV benefit
of liraglutide [9].
All types of vascular disease were attenuated
with liraglutide, including MI, stroke and heart
failure, even though statistical significance
could not be demonstrated for individual
endpoints. It is certain, however, that the
benefits of the drug extended to all vascular
beds and to the myocardium as well.
Comparison with Other Trials
It is self-evident that various CVO trial results be
compared with each other (Table 2). However, it
must be noted that CVO trials are not
head-to-head trials of two molecules [barring a
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Table 1 LEADER data summary
Parameter Outcome Key ﬁndings
Positive CV
parameters
MACE—primary endpoint Signiﬁcant reduction (13%) in MACE events
MACE: individual components 22% reduction in CV death
12% reduction in non-fatal MI
11% reduction in non-fatal stroke—ﬁrst CV outcome
study in diabetes segment to demonstrate reduction
in non-fatal stroke
Expanded MACE: MACE ? coronary
revascularization, or hospitalization for
unstable angina pectoris or heart failure
Signiﬁcant (12%) reduction
Myocardial infarction Fatal: 40% reduction
Non-fatal: 12 % reduction
Silent: 14% reduction
Stroke Fatal: 36% reduction
Non-fatal: 11% reduction
Transient ischemic attack 21% reduction
Coronary revascularisation 9% reduction
Death from any cause 15% reduction





HbA1c At 36 months liraglutide arm had better HbA1c
control of -0.40% compared to the placebo group
Weight loss At 36 months liraglutide arm demonstrated better
weight reduction (-2.3 kg from baseline)




Hypoglycaemia, conﬁrmed 20% in liraglutide group
Hypoglycaemia, severe 31% in liraglutide group
Antihyperglycaemic medications introduced
during the study
The number of antihyperglycaemic medications was
more in placebo group than liraglutide group
Neutral safety
parameters
Adverse events, severe No difference
Adverse events, serious No difference
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few exceptions such as DEVOTE
(NCT01959529), CAROLINA (NCT01243424)
and TOSCA. IT (NCT00700856)] [10–12]. The
results of these trials are influenced by various
factors in study design such as inclusion criteria,
baseline medication use, quality of ‘standard of
care’, duration of follow-up, and statistical plan.
This implies that while LEADER and EMPA-REG
OUTCOME (NCT01131676) can be discussed
together, their results cannot be compared
numerically. While EMPA-REG OUTCOME has
been able to demonstrate CV benefits of
empagliflozin, there are subtle differences in
its results, as compared to those of liraglutide.
Liraglutide has a gradually developing positive
effect on all aspects of CV disease and mortality,
while empagliflozin has a relatively faster effect
on CV mortality and heart failure, but a
numerically negative effect on stroke [7]. The
number needed to treat (NNT) to prevent
coronary events or deaths is much lower with
empagliflozin than with liraglutide (Table 2).
This raises questions about the economic
viability of extrapolating the results of these
trials to routine clinical practice. ELIXA
(NCT01147250), which studied lixisenatide, a
shorter acting glucagon-like peptide-1 receptor
agonist (GLP-1 RA), has demonstrated CV safety
of the molecule, but could not find significant
CV benefit of its use [8].
Calorie Restriction Mimicry
The authors of LEADER suggest that liraglutide
modifies progression of atherosclerotic disease
[9]. We highlight another facet of this drug
which can be used to explain its beneficial
action. Calorie restriction has long been known
to improve longevity in both animal and
human species [13]. Calorie restriction
mimicry, using drugs designed to act on the
adenosine monophosphate kinase (AMPK)
pathway, in a manner similar to that of calorie
restriction, has also been tried to achieve similar
benefits. Perhaps, the most well-known calorie
restriction mimetic is metformin, which has
also shown improved outcomes in the UKPDS
(United Kingdom Prospective Diabetes Study)
trial (ISRCTN 75451837) [14].
Liraglutide acts as a direct calorie restrictor
by reducing appetite, and also as a calorie
restriction mimetic by modifying AMPK
action. Its actions on the hypothalamus,
gastrointestinal tract and pancreas are
designed to mimic a state of calorie restriction
[13, 15, 16]. This facet of liraglutide’s
mechanism of action needs detailed study.
Cholelithiasis
Another facet of the LEADER study that
deserves close attention is the incidence of
cholelithiasis. LEADER reports exceptional
Table 1 continued
Parameter Outcome Key ﬁndings
Pancreatitis, acute No difference




Acute gallstone disease More in liraglutide arm (n = 145) than in placebo arm
(n = 90)
CV cardiovascular, MACE major adverse cardiovascular events
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safety and tolerance with liraglutide, finding no
increase in the risk of pancreatitis or neoplasms.
There is, however, a higher risk of cholelithiasis
in persons treated with liraglutide [9]. Risk
factors for cholelithiasis that operate in the
general population also tend to occur in
participants of CVO trials. These include older
age, female gender, heavy body weight and
Table 2 Differences between LEADER, EMPA-REG and ELIXA
Parameter LEADER EMPA-REG ELIXA
Study drug Liraglutide Empagliﬂozin Lixisenatide




Baseline HbA1C (%) 8.7 8.07 7.7
Baseline BMI (Kg/m2) 32.5 30.6 30.1








13% 14% 2% increase
(P not signiﬁcant)
CV death reduction 22% 38% NA
Non-fatal MI reduction 12% 13% NA
Non-fatal stroke 11% reduction 24% increase NA
Death from any cause
reduction
15 % 32% 6%
Weight reduction at the end
of the study
2.3 kg 1.4 kg 0.7 kg
Time to beneﬁt 12–18 months 4–8 weeks Non-inferiority to
placebo established
No observed beneﬁts










NNT to prevent one death
over *3 years
98 39 N/A
CV cardiovascular, NNT number needed to treat
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hypertriglyceridemia [17]. A higher incidence of
gallstones has also been reported with exenatide
[18].
While GLP-1-specific mechanisms have been
postulated for this, such as reduced
cholecystokinin, slower biliary tract motility
and increased stasis of bile, it must be noted
that cholelithiasis is a risk inherent to every
weight-lowering therapy, including very
low-calorie diet [19]. Gallstones may develop
as soon as 4 weeks after initiation of
weight-reducing diet. Hypotheses that have
been suggested include an increase in
cholesterol output, due to increased
mobilization of tissue cholesterol to bile;
increased gall bladder secretion of mucin and
calcium; increased presence of prostaglandin E2
and arachidonic acid in bile; super-saturation of
cholesterol in bile, due to reduced bile salt
secretions; gall bladder stasis due to reduced
stimulation by low-fat diet [20].
Primary and Secondary Prevention
Liraglutide provides comprehensive metabolic
modulation, including weight, systolic blood
pressure and lipid control. Similar results are
seen with empagliflozin as well. Once again,
subtle differences are visible to the discerning
eye. Empagliflozin has a diuretic effect, and
reduces both systolic and diastolic blood
pressure, without causing reflex tachycardia.
However, its effects on lipid profile are not
significant. Direct hemodynamic effects on the
heart and vasculature are also suggested, as it
has a more marked benefit on heart failure than
on coronary events [21]. Liraglutide has a
greater effect on body weight, systolic blood
pressure and lipids, and seems to modify the
progression of the basic atherosclerotic process
in diabetes.
It may be that liraglutide prevents the actual
CV event (primary prevention) while
empagliflozin reduces mortality after the event
(secondary prevention) [22]. However, though
the numerical data from LEADER are in favor of
this statement, more research is needed to
support this claim.
Richard the Lionheart and Robin Hood
The ‘Robin Hood effect’ has been suggested as a
moniker for the metabolic effects of sodium
glucose cotransporter-2 (SGLT2) inhibitors,
which shift energy production from
carbohydrate metabolism to lipid metabolism
[23]. In a similar (Anglo-centric) vein, the term
Lion Heart effect may be used to describe
liraglutide. Richard the Lionheart was an
iconic twelfth century English king who was
famous for his military prowess. Richard the
Lionheart and Robin Hood are shown as
contemporaries in various quasi-historical
accounts. The results of LEADER suggest a
Ricardian property of liraglutide, which
provides vascular safety and benefit, and
modifies the natural history of diabetes in a
favorable manner.
Influence and Impact: Follow the LEADER
The LEADER trial, which studied the effect of
liraglutide on CVO has changed much more
than the clinical usage of liraglutide. Reported
recently, its results place LEADER in the same
league as the DCCT (Diabetes Control and
Complications Trial) (NCT00360815) and
UKPDS trials [24, 25]. These studies have
contributed immeasurably to modern diabetes
care, and their impact cannot be understated.
The results of ongoing trials such as EXSCEL
(exenatide once weekly) and REWIND
(dulaglutide) will also modify the way in
which we view LEADER [25, 26]. The
EXenatide Study of Cardiovascular Event
Lowering (EXSCEL) study (NCT01144338) will
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assess the impact of exenatide once weekly on
major CV outcomes. EXSCEL is a double-blind,
pragmatic placebo-controlled trial being
conducted in 35 countries on 14,000
participants with type 2 diabetes mellitus
(T2DM) and a broad range of CV risk over
approximately 5 years. The Researching
Cardiovascular Events With a Weekly Incretin
in Diabetes (REWIND) trial (NCT01394952),
being carried out in 9600 participants over
nearly 7 years, evaluates whether dulaglutide,
administered by a once-weekly injection, can
prevent the appearance of CV complications in
people with type 2 diabetes. Both EXSCEL and
REWIND results will be eagerly awaited, to see if
the benefits obtained in LEADER are liraglutide
specific or are a class effect of long-acting and
intermediate-acting GLP1-RA.
Liraglutide has shown robust benefits, which
extend beyond its glucose-lowering effect.
Currently, it is the only glucose-lowering drug
which is approved for use as an anti-obesity
treatment in euglycemic persons as well.
LEADER adds to this spectrum of use by
encouraging its use in persons with diabetes at
high risk of CV disease, and high risk of renal
disease. The drug has been shown to have both
macro- and micro-vascular benefits, and this
allows its use as a pan-vascular preventive
molecule apart from being a glucose-lowering
treatment. LEADER data suggest that liraglutide
can be used for secondary prevention
(prevention of MI and stroke), and strongly
supports its use for tertiary prevention
(prevention of fatality after occurrence of MI
or stroke). Long-term studies are still required to
assess its utility in primary prevention, i.e.,
prevention of CV events and death in persons
without diabetes or other lower risk
populations.
CONCLUSION
The LEADER trial contributes to the evolution
of diabetes care in a significant manner, and will
certainly find a place as a milepost in the history
of diabetes. Its results provide evidence that a
single drug can be used to provide not only
comprehensive glycemic and metabolic control
but also achieve beneficial CV outcomes. These
benefits occur at all vascular bed sites, viz.,
coronary and cerebrovascular, and do not
impair myocardial function (as shown by lack
of increase in heart failure). Viewed from this
vantage point, LEADER should immensely help
improve the way in which we care for people
with diabetes.
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